SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IPIC
IPIC 0.00010000.0%Aug 15 3:35 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: NeuroInvestment who wrote (1003)1/31/1998 11:36:00 PM
From: WeirdPro Randy  Read Replies (1) of 1359
 
<< The rumors I have heard about the study have thus far been along the line of an absence of valvular pathology in Redux II users.>>
While this is not the end-all study as it is not a double-blinded, placebo type study, it would seem very pertinent in light of comments you (NeuroInvestment)have made:
1) The mean duration of Redux use in the US was 2 months.
2) Only 4% of Redux users were of greater than 6 months duration.
It would seem a good outcome from this study should significantly help explicate over 90% of Redux users with concerns of causality issues( and making the concerns of negligence a moot point).

And again as you have said, with 73 Redux patients so far, out of 12 million users, with reports of valvular heart disease, this kind of lends support to the rumors.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News